Evaluate the Efficacy of Adding Intraluminal Brachytherapy After CCRT for Local-regional Thoracic Esophageal Cancer.

Launched by TAIPEI VETERANS GENERAL HOSPITAL, TAIWAN · Apr 10, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new treatment option for patients with thoracic esophageal cancer. Researchers want to see how well a special type of radiation therapy called intraluminal brachytherapy works when added after standard treatment, which includes chemotherapy and radiation (known as CCRT). This study aims to find out if this additional treatment is safe and helps improve the outcomes for patients with this type of cancer.

To participate in the trial, individuals should be between 20 and 85 years old and have a confirmed diagnosis of thoracic esophageal cancer, which can be at various stages (I-IV). They should have completed the standard treatment of CCRT with specific radiation doses. However, those with certain complications, such as severe narrowing of the esophagus or those who are already involved in other trials, may not be eligible. If you join this trial, you will receive close monitoring and care as part of the study to assess the treatment's effectiveness and safety.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age of 20-85 years, with ECOG performance 0-2.
• • Thoracic esophageal cancer with clinical stage I-IV and biopsy proof; patient with stage I-IV cervical esophageal cancer could be recruited in this trial according to Investigator's assessment.
• • Complete CCRT with total doses of 45-55Gy to GTV via external beam radiotherapy (EBRT).
• Exclusion Criteria:
• • According to Investigator's assessment, patients with double cancer or recurrence could be recruited in this trial if they continue to receive systemic therapy.
• • Patient with double cancer, esophageal cancer or recurrence who is scheduled for surgery treatment.
• • Involvement of tracheal mucosa or bronchial mucosa.
• • Stenosis of esophageal lumen that cannot be bypassed by the applicator after EBRT.
• • The distribution of the lesions of interest exceeds 10cm range.
• • The patient is participating in other clinical trials.